[20110526. Issues on duodenal ulcer (8): selection of medication for maintenance treatment]
¿À´ÃÀº Áõ·Ê Çϳª¸¦ º¸¿©µå¸³´Ï´Ù. ù »çÁøÀº ±Ë¾çÄ¡·á ÈÄ È£ÀüµÈ ¹ÝÈçÀÌ°í µÎ¹ø° »çÁøÀº Àç¹ß ´ç½ÃÀÇ È°µ¿¼º ±Ë¾çÀÔ´Ï´Ù. ½ÊÀÌÁöÀå±Ë¾çÀº Á¤¸» Àç¹ßÀÌ ¸¹½À´Ï´Ù. ´ëºÎºÐÀÇ ±Ë¾çÀº Ç︮ÄÚ¹ÚÅÍ °¨¿°À̳ª NSAIDs¿Í °ü·ÃµÇ¾î ÀÖ½À´Ï´Ù.
Àú´Â ¼Òȼº ±Ë¾çÀÇ Ã¹ Ä¡·á¾àÁ¦·Î PPI¸¦ ¼±ÅÃÇÏ°í ÀÖ½À´Ï´Ù. H2RA¸¦ ½áµµ µË´Ï´Ù¸¸ °£È¤ H2RA·Î ¾Æ¹°Áö ¾Ê´Â ±Ë¾çȯÀÚ°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ H2RA ÀúÇ×¼º ¼Òȼº±Ë¾ç¿¡¼ PPI°¡ È¿°úÀûÀÔ´Ï´Ù (Asaka, 1992). ÇÑ ¾Ë °¡°ÝÀ¸·Î µûÁöÁö ¾Ê°í ÇÏ·ç Åõ¾à ¿ë·®°ú Åõ¾à±â°£À» °í·ÁÇϸé PPI°¡ ´õ ºñ½Ñ °Íµµ ¾Æ´Õ´Ï´Ù. ªÀº ±â°£ Åõ¾àÀ̹ǷΠsafety profileµµ ÁÁ½À´Ï´Ù. ÇÏ·ç ÇѹøÀÇ Åõ¾à¹æ¹ýµµ ¸¶À½¿¡ µì´Ï´Ù. °á±¹ PPI ´ë½Å H2RA¸¦ ¼±ÅÃÇÒ ÀÌÀ¯°¡ ¾ø´Â °ÍÀÔ´Ï´Ù. ´Ü ¿¹¿Üµµ ÀÖ½À´Ï´Ù. ¼Òȼº±Ë¾çÀÌ ³Ê¹« ½ÉÇÏ°í circumferentialÇϸé H2RA¸¦ °í·ÁÇÕ´Ï´Ù. Overtreatment¸¦ ¿ì·ÁÇϱ⠶§¹®ÀÔ´Ï´Ù (EndoTODAY risk of overhealing).
¼öÁÖ°£ PPI¸¦ ½è´Ù°í ±Ë¾çÄ¡·á°¡ ´Ù ³¡³ °ÍÀº ¾Æ´Õ´Ï´Ù. Àç¹ß·üÀÌ ³ô±â ¶§¹®ÀÌÁö¿ä. 2000³â Kaneco´Â PPI·Î Ä¡·á ÈÄ half dose H2RA·Î À¯ÁöÇÑ È¯ÀÚ±º¿¡ ´ëÇÏ¿© ´ÙÀ½°ú °°ÀÌ ½è½À´Ï´Ù. At 1 year after the start of maintenance therapy, the recurrence rates were 25% for GU and 39% for DU patients. In DU patients, the recurrence rates from S1-stage and S2-stage were 49% and 20%, respectively (P = 0.004). ÀÌ ¿¬±¸¿¡¼ÀÇ Àç¹ßÀº ³»½Ã°æÀû Àç¹ßÀÔ´Ï´Ù. Áõ»óÀÌ ÀÖ¾ú°Å³ª ÃâÇ÷°ú õ°ø°ú °°Àº ÇÕº´ÁõÀÌ ÀÌ·¸°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ¿©ÇÏÆ° ½ÊÀÌÁöÀå±Ë¾ç¿¡¼ H2RA ´Üµ¶ À¯Áö¿ä¹ýÀº ´Ù¼Ò ¾àÇÑ Àü·«ÀÔ´Ï´Ù. Á¦±ÕÄ¡·á°¡ ÇʼöÀÔ´Ï´Ù. NSAID µî ´Ù¸¥ Àç¹ß¿äÀÎÀÌ ¾ø´ÂÁöµµ È®ÀÎÇØ¾ß ÇÕ´Ï´Ù.
¿À·¡µÈ ¸®ºä¿¡ ÀÌ·± ¸»ÀÌ ÀÖ¾ú½À´Ï´Ù (Hunt, 1995). H. pylori eradication by 1-2 weeks' treatment with a combination of a PPI and two antimicrobial agents appears to be the optimal (and probably the most cost-effective) approach to the long-term management of patients with peptic ulcer disease, and represents a major advance in the management of such patients. Á¦±ÕÄ¡·á°¡ ¼Òȼº±Ë¾ç Àç¹ß¹æÁö¸¦ À§ÇÑ °¡Àå ÁÁÀº ¹æ¹ýÀÌ°í ºñ¿ëÈ¿°úÀ̶ó´Â °ÍÀÔ´Ï´Ù. Àúµµ ¿©±â±îÁö´Â µ¿ÀÇÇÕ´Ï´Ù.
±×·±µ¥ °ú¿¬ Á¦±ÕÄ¡·á¸¸ ÇÏ¸é ¸¸»ç OKÀϱî¿ä? ´ÙÀå±âÁúȯÀ» °¡Áø °í·É ȯÀÚ¿¡¼ Á¦±ÕÄ¡·á¸¸ ÇÏ¸é ³¡Àϱî¿ä? NSAID¸¦ °è¼Ó »ç¿ëÇØ¾ß Çϴ ȯÀÚ´Â ¾î¶»°Ô ÇØ¾ß ÇÒ±î¿ä? Çѹø¸¸ ´õ Àç¹ßÇϸé Å« ÀÏÀÌ ³¯ °Í °°Àº »ç¶÷¿¡¼, ¿¹¸¦ µé¸é ¾ÆÁ÷ ¼ö¼úÇÒ ´Ü°è´Â ¾Æ´ÏÁö¸¸ ½ÉÇÑ ÇùÂøÀÌ ¹ß»ýÇÑ È¯ÀÚ¿¡¼µµ Á¦±ÕÄ¡·á¸é ÃæºÐÇÒ±î¿ä?
Ohara´Â H. pylori-negative recurrent peptic ulcer¿¡ ´ëÇÑ Èï¹Ì·Î¿î ³í¹®À» ¹ßÇ¥ÇÑ ¹Ù ÀÖ½À´Ï´Ù.
ÀÌ ¸ðµç °ÍÀ» °í·ÁÇÏ¿© Àú´Â Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á¸¦ ÇÑ ÈÄ¿¡µµ (Ç︮ÄÚ¹ÚÅÍ°¡ Àß ¾Ë·ÁÁö±â ÀÌÀüÀÇ) À¯Áö¿ä¹ý ÀûÀÀÁõ¿¡ ÇØ´çÇϴ ȯÀÚ, ƯÈ÷ ¿©·¯ À§ÇèÀÎÀÚ¸¦ °¡Áø ȯÀÚ¿¡¼ PPI¸¦ ÀÌ¿ëÇÑ longterm maintenance treatment¸¦ ±ÇÇÏ°í ÀÖ½À´Ï´Ù. PPI¸¦ ¸ÅÀÏ µå½Ç ÇÊ¿ä´Â ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù. Half dose PPI¸¦ ÀÏÁÖÀÏ¿¡ 2¹ø Á¤µµ µå½Ã´Â °ÍÀ¸·Îµµ ´ëºÎºÐÀÇ È¯ÀÚ¿¡¼ ¼Òȼº±Ë¾ç Àç¹ßÀÌ ¿¹¹æµË´Ï´Ù. °³ÀÎÀûÀÎ °æÇèÀÔ´Ï´Ù¸¸...
¾Æ·¡ ȯÀÚ´Â ½ÊÀÌÁöÀå ±Ë¾çÀÌ ¹Ýº¹µÇ¾î °í»ýÀÌ ¸¹À¸¼Ì´ø ºÐÀÔ´Ï´Ù. Helicobacter Á¦±Õ Ä¡·á ÈÄ¿¡µµ half dose PPI¸¦ ÀÏÁÖÀÏ¿¡ µÎ¹ø µå½Ãµµ·Ï ±ÇÇß½À´Ï´Ù. AspirinÀ» µå½Ã°í ÀÖ´Â °í·É ȯÀÚ¶ó´Â Á¡À» °í·ÁÇÏ¿´½À´Ï´Ù.
Pentax Imagina ³»½Ã°æÀ¸·Î ÃÔ¿µ
[Home]